BioSpace News Archive

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company developing its Nano-Pulse Stimulation™ (NPS™) technology, today announced financial results for the third quarter ended September 30, 2020. Recent Highlights Submitted a 510(k) Premarket Notification application to the U.S. Food and Drug Administration (FDA) for the CellFX ® System seeking to obtain initial clearance for a general

Tricida, Inc. (Nasdaq: TCDA), announced today financial results for the three and nine months ended September 30, 2020 and provided an update on key initiatives.

Reports record Breast Products net sales of $15.3 million, representing 54% sequential growth and 2 1 % year over year growth Results driven by U.S. recovery and market outperformance in the core breast products segment

Cerecor Inc., a biopharmaceutical company focused on becoming a leader in development and commercialization of treatments for rare and orphan diseases, announced recent business progress and third quarter results for 2020.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months ended September 30, 2020.

Organogenesis Holdings Inc., a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, reported financial results for the three and nine months ended September 30, 2020.

Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2020.

Novavax, Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced updates to its leadership team, including the appointment of Gregory F. Covino as Executive Vice President and Chief Financial Officer (CFO).

DNAtrix, a biotech company advancing virus-driven immunotherapies for cancer, today announced that four abstracts on the company’s platform technology have been accepted for presentation at the 25th Annual Scientific Meeting and Education Day of the Society for Neuro-oncology (SNO) to be held November 19-21, 2020.

Amgen (NASDAQ:AMGN) today announced that data from its cardiovascular (CV) portfolio will be presented at the American Heart Association (AHA) Scientific Sessions 2020: A Virtual Experience, Nov. 13-17, 2020.